Drugs / AutoVac™
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00068614 | Jul 2003 → Oct 2005 | breast cancer | Case Comprehensive Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AutoVac | “Patients receive HER-2 protein AutoVac™ intramuscularly at weeks 0, 2, 6, and 10 in the absence of unacceptable toxicity.” NCT00068614 ↗ |
| Known as | PX104.1.6 | “A Phase I Trial Evaluating The Safety Of Intramuscular Injections Of HER-2 Protein AUTOVAC (PX104.1.6) In Patients With Breast Cancer” NCT00068614 ↗ |
| Modality | Vaccine | “HER-2/neu peptide vaccine” NCT00068614 ↗ |
| Route | Intramuscular | “intramuscularly” NCT00068614 ↗ |